Incyte/$INCY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Incyte
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Ticker
$INCY
Sector
Primary listing
Employees
2,617
Headquarters
Website
Incyte Metrics
BasicAdvanced
$16B
18.68
$4.37
0.68
-
Price and volume
Market cap
$16B
Beta
0.68
52-week high
$82.15
52-week low
$53.56
Average daily volume
1.7M
Financial strength
Current ratio
2.85
Quick ratio
2.553
Long term debt to equity
0.761
Total debt to equity
1.017
Interest coverage (TTM)
394.96%
Profitability
EBITDA (TTM)
1,060.902
Gross margin (TTM)
53.22%
Net profit margin (TTM)
18.99%
Operating margin (TTM)
21.08%
Effective tax rate (TTM)
31.02%
Revenue per employee (TTM)
$1,750,000
Management effectiveness
Return on assets (TTM)
11.52%
Return on equity (TTM)
24.30%
Valuation
Price to earnings (TTM)
18.683
Price to revenue (TTM)
3.442
Price to book
3.8
Price to tangible book (TTM)
4.07
Price to free cash flow (TTM)
16.689
Free cash flow yield (TTM)
5.99%
Free cash flow per share (TTM)
4.89
Growth
Revenue change (TTM)
18.87%
Earnings per share change (TTM)
900.04%
3-year revenue growth (CAGR)
11.36%
10-year revenue growth (CAGR)
21.68%
3-year earnings per share growth (CAGR)
0.97%
10-year earnings per share growth (CAGR)
49.74%
What the Analysts think about Incyte
Analyst ratings (Buy, Hold, Sell) for Incyte stock.
Incyte Financial Performance
Revenues and expenses
Incyte Earnings Performance
Company profitability
Incyte News
AllArticlesVideos
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
CNBC Television·2 weeks ago
Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand
Benzinga·2 weeks ago
Incyte lifts annual sales forecast for blood cancer drug after solid quarter
Reuters·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Incyte stock?
Incyte (INCY) has a market cap of $16B as of August 16, 2025.
What is the P/E ratio for Incyte stock?
The price to earnings (P/E) ratio for Incyte (INCY) stock is 18.68 as of August 16, 2025.
Does Incyte stock pay dividends?
No, Incyte (INCY) stock does not pay dividends to its shareholders as of August 16, 2025.
When is the next Incyte dividend payment date?
Incyte (INCY) stock does not pay dividends to its shareholders.
What is the beta indicator for Incyte?
Incyte (INCY) has a beta rating of 0.68. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.